Following ASH 2023, a hematologist-oncologist discusses recent updates on approved and emerging therapies for patients with leukemia, highlighting the TRANSFORM-1 trial looking at navitoclax plus ruxolitinib.
Hackensack University Medical Center’s heart experts are taking this time to celebrate their leadership in cardiovascular care. The hospital is the only cente
Hackensack University Medical Center’s heart experts are taking this time to celebrate their leadership in cardiovascular care. The hospital is the only cente